WHAT THIS PAPER ADDS

What is already known about this subject:
Many products are applied to human skin for local effects in deeper tissues. Animal studies suggest that deep dermal and/or subcutaneous delivery may be facilitated by both dermal diffusion and transport via the cutaneous vasculature. However, the relationship between the extent and pathways of penetration, drug physicochemical properties and deeper-tissue physiology are not well understood.
What this study adds:
We have used a physiological-based pharmacokinetic model to analyse human cutaneous microdialysis literature, complemented by our own in vitro skin penetration studies. We find that convective blood, lymphatic and interstitial flow lead to significant deep-tissue concentrations for drugs that are highly plasma protein bound. In such cases, deeper-tissue levels will occur earlier and may be several orders of magnitude greater than predicted by passive dermal diffusion alone. infective and antifungal agents [1] . For such drugs, understanding the penetration behaviour into deep dermal tissue layers is critical for therapeutic success and early work has shown that direct and significant penetration of therapeutic solutes deep into human skin after topical application can occur [2] . In general, therapeutic concentrations of drugs being targeted to deeper tissues after topical application in man are assessed using either cutaneous microdialysis [3] [4] [5] or by biopsy [6, 7] . In contrast, deep dermal transport is probably undesirable for drugs being applied in transdermal delivery systems for systemic effects as transport into deep dermal tissue layers may be associated with sequestration, metabolism and a lack of a therapeutic advantage. Indeed, human cutaneous microdialysis studies of topically applied nicotine for smoking cessation suggests that nicotine is not delivered to deeper tissues in high concentrations [8] . The relationship between the extent and mechanisms of drug penetration into deep dermal tissue after topical application, solute properties and skin physiology is controversial [9] . We and others have deduced from rat wound deposition studies that diffusion governs penetration into deep tissue and that drug molecular weight is the key physicochemical determinant of underlying tissue concentrations [10] [11] [12] . Other studies in rats [13] and in pigs [14] are suggestive that penetration of topically applied drugs into deep skin layers also involves the cutaneous microvasculature. Our own work suggests that methylsalicylate induced increased in cutaneous blood flow can promote the deeper penetration of salicylate from topically applied methylsalicylate [15] . 
MATERIALS AND METHODS
Chemicals
The drugs used were diclofenac acid (Amoli Organics, Mumbai, India), fluconazole, ibuprofen, 
Preparation of dermal tissue
Female abdominal skin was obtained from two donors following abdominoplasty in accordance with human ethics approval from the Princess Alexandra Hospital Human Ethics Committee. Fat and subcutaneous tissues were removed using blunt dissection. The epidermis and the dermis were separated using the heat separation technique (immersion in water at 60 °C for 1 minute) [18] .
In vitro penetration study
Skin penetration studies were carried out using side-by-side diffusion cells immersed in a water bath at 36 ˚C, n = 6 for each drug. The donor and receptor volumes were 1.5 mL and the mean surface area of penetration was 1.12 ± 0.03 cm 2 . Both sides of the dermis were first equilibrated at 36 ˚C for 4 h with 1.5 mL PBS at pH 7.4 with 4% BSA in the donor and receptor compartments of the side-by-side cells. After equilibration, the PBS with 4% BSA was removed from both compartments. It was replaced on the donor side of the cells with 1.5 mL of the drug under consideration in PBS at pH 7.4 for fluconazole (890 µg/mL), lidocaine (1190 µg/mL) and propranolol (880 µg/mL) and PBS with 4% BSA at pH 7.4 in the cases of diclofenac (690 µg/mL), ibuprofen (820 µg/mL) and nicotine (5300 µg/mL). The receptor side of the cells was filled with either 1.5 mL of either PBS or PBS with 4% BSA at pH 7.4. The presence of BSA in both the donor and receptor phases mimicked the physiological conditions of dermis in vivo (we assumed it didn't alter the dermis transport properties). It is also a standard addition to receptor solutions for in vitro skin penetration studies of lipophilic compounds [19] . exposed dermis was cut from the rest of the piece of skin and weighed. The thickness of the dermis was measured between two microscope glass slides using an electronic calliper. To measure the solute concentration remaining in the skin, the dermis pieces were cut in smaller pieces and placed in 500 µL acetonitrile for at least 12 h for extraction.
Determination of fraction unbound to albumin
The fraction of permeant unbound to BSA was determined by ultrafiltration. 500 µL of 
HPLC analysis
The HPLC system (Shimadzu, Kyoto, Japan) generally consists of a Shimazu LC-10AD pump; a 
Physiologically based pharmacokinetic model used to analyse in vivo diclofenac and nicotine human microdialysis data
In this analysis, we used the physiological pharmacokinetic model that we have recently described [6] using the particular form of the model in which the permeability of blood and lymphatic vessels was not rate limiting in solute transport. We have previously shown that such a model adequately described the distribution and clearance of highly protein bound solutes in a perfused hind limb after topical application [20] . An important addition to the model is the recognition of interstitial convection associated with capillary flow and draining of the interstitial space ( Figure 1A ). Here, our detailed model analysis used serial cutaneous microdialysis concentration -time profiles available at two depths in the skin of individual human volunteers [16, 17] below the epidermis ( Figure 1B) . Importantly, our analysis was unaffected by the nature of solute penetration through the stratum corneum. Stratum corneum thickness, and therefore the penetration lag time to the epidermal-dermal junction and beyond, can vary with body site [21] .
In Muller et al's microdialysis studies, diclofenac was applied to the thigh and nicotine was 
All data fits and standard deviations were obtained using SCIENTIST (MicroMath Scientific Software, Salt Lake City, UT, USA).
The relative concentrations for diclofenac and nicotine in a probe at a depth of 4.5 mm below a superficial probe, in which the drug concentration is a constant value of , is given by the At long times (steady state), the inversion of equation (5) is given by s. f(s) where s 0, i.e., the steady state relative concentrations are given by (6) As the expression for time lag in a diffusion-reaction system is quite complex [22] we have defined lag time in the deep probe for a constant input concentration in the superficial probe as the time taken to reach 0.01 of that input concentration as defined by Eq. 5. 
RESULTS
Comparison of in vitro dermis and in vivo dermis/deep tissue penetration lag times Table 1 compares the in vitro lag times for diclofenac, fluconazole, ibuprofen, lidocaine, nicotine and propranolol obtained from our dermis penetration experiments to published in vivo data.
Diclofenac and ibuprofen are highly BSA-bound (fu BSA = 0.05 and 0.11, respectively). The in vitro lag times determined in our experiments are 5 to 18 times larger than observed in vivo lag times in subcutaneous and muscle tissue ( Table 1 ). The fraction of propranolol unbound to BSA was determined to be 0.57, and the mean in vitro lag time we calculated is 5 to 6 times greater than that reported by Stagni et al. [23] for the iontophoretic delivery of propranolol into dermal and subcutaneous tissue. On the other hand, fluconazole and nicotine remain mostly unbound to BSA (fu BSA = 0.85 and 0.91, respectively). These drugs yielded in vitro lag times which are on the same order of magnitude as the observed in vivo lag times into dermis and deeper tissues.
The in vitro lag time of mostly unbound (fu BSA = 0.90) lidocaine from an aqueous solution was 44 min, similar to that reported for unionized lidocaine across dermatomed human skin [24] , to the observed in vivo human skin lag times of about 70 min for a eutectic topical product [25] as well as to the lower range 45 min for a microemulsion formulation [26] .
The relative penetration of diclofenac and nicotine in deep subcutaneous skin layers
We used our results for the in vitro penetration of these drugs through excised human dermis (Table 1) to analyse the reported in vivo deep tissue penetration of diclofenac and nicotine [16, 17] . Figures 2A and B show regressions obtained using diclofenac and nicotine data sets using our physiological pharmacokinetic model at different cutaneous microdialysis depths (3.2 and 9.1 mm for diclofenac; 2.0 and 4.5 mm for nicotine). When transport was assumed to be by tissue diffusion and constant elimination alone, the model poorly described the diclofenac data ( Figure 2A ) but adequately described the nicotine data ( Figure 2B ). In contrast, a satisfactory regression fit to the microdialysis concentration profile of diclofenac at a depth of 9.1 mm was obtained assuming transport by a model that included convective blood, lymphatic and convective flow transport (Figure 2A ). This latter regression yielded an apparent in vivo dermal dispersion coefficient of (5. would be predicted by the in vitro dermis diffusion coefficient. As elucidated more fully in the discussion, a high apparent in vivo dispersion coefficient most likely reflects blood convection, lymphatic and convective dispersion caused by the variation in flows and vasculature orientation as originally described as a carriage mechanism modifying convective blood transport of drugs in the liver by Roberts & Rowland [27, 28] . and, most recently, in the dermis by Anissimov and
Roberts [6] where dispersion was also suggested to arise from lymphatic flow.
In contrast, regression using the in vivo nicotine concentration profile at a depth of 4.5 mm leads to a much smaller apparent in vivo dermal dispersion coefficient of (1.8 ± 0.9)·10 
DISCUSSION
A major finding in this work is that transport of highly plasma protein bound drugs into deeper dermal tissues occurs several orders of magnitude faster than predicted by passive dermal
diffusion. There appears to be no concentration-depth gradient for highly bound drugs in the papillary dermis adjacent to the application site, and only a small gradient in the recticular dermis. In contrast, a substantial concentration-depth profile is apparent for poorly protein bound drugs and predicted for highly bound drugs using in vitro dermis diffusion coefficients.
Convective transport apparently ameliorates the concentration-depth profile predicted from dermal diffusion alone: the nature of the convective blood, lymphatic and interstitial flow affecting drug distribution is different in the papillary and reticular dermis ( Figure 3A ).
The majority of cutaneous blood vessels are located in the top 1 to 2 mm of the skin [31] .
Adjacent lymphatic capillaries begin deeper and drain vertically into lower dermal and upper subcutaneous vessels, without anastomosing with blood vessels [32] . Figure 3B shows the distribution of blood-vessel surface area to total skin surface area is effectively constant down to 2 mm, then decreases quasi-exponentially. This structure supports a "well-stirred" mixing behaviour below 2 mm, with no concentration-depth gradient for highly bound drugs. Contrary to Muller et al. [16] , Hegemann et al. [8] reported no correlation between nicotine concentration and probe depth (0.57 to 1.22 mm), possibly because of higher blood vessel density in superficial skin layers (Figure 4 ). The high inter-subject variability in human in vivo studies may obfuscate a concentration-probe depth correlation: similar studies with inbred rat species [33] have revealed such correlations, where inter-subject variability is lower. No such correlation was found in Ref.
[34], perhaps due to different distances between probes. where there is a lower vessel density, fewer interconnections and less flow ( Figure 3A , 3B), highly protein bound drugs appear to have weak concentration gradients, whereas poorly bound drugs show an exponential concentration gradient (see Table 1 for examples). Exceptions are ibuprofen (fu BSA = 0.11) and lidocaine (fu BSA = 0.90) ( Table 1 ). The data for ibuprofen refers to muscle versus subcutaneous tissue [36] and suggests that high blood clearance in the muscle is more significant than convective transport in the dermis and subcutaneous tissue. For lidocaine, a high skin barrier function inter-individual variability is observed, and the potential dependence of dialysate concentration on probe depth not described [26] .
In principle, convective transport of solutes to deeper tissues is a much faster process than tissue diffusion. In general, lag times for measurable microdialysate levels of protein-bound drugs in deeper tissues are shorter than predicted from in vitro dermal diffusion alone ( Table 1 ).
The penetration from the papillary dermis into subcutaneous tissue is significantly faster in vivo than in vitro penetration into excised dermis. For strongly protein bound drugs, the in vivo:in vitro lag time ratios into dermis and deeper tissue are 1:5 for ibuprofen and <1:18 for diclofenac. Anderson et al. [25] (the lag time varies highly between subjects and the nature of the product used in these studies). Aqueous solutions used in our in vitro experiments would likely have induced a higher skin hydration level than the various products of Ref. [26] in vivo, reducing the epidermal penetration lag time. In vivo lag times can be estimated from the first microdialysis time point at which drug is detected. This overestimates the actual lag time if significant drug is detected at this point (as seems the case for diclofenac, see Figure 2A hydrocortisone [6] . The higher blood and lymphatic vessel availability below the application site ( Figure 3 ) can increase the penetration of topically applied substance into deep cutaneous tissue layers [13, 14] . Consequently, the in vivo dermal nicotine dispersion coefficient deduced from regression ( Figure 2B ) for the convection-diffusion model at 9.1 mm is about 4 times the in vitro diffusion coefficient of excised dermis.
For propranolol (which has similar lipophilicity as ibuprofen but is less protein bound) Stagni et
Additional processes affect the transport of highly protein bound drugs, which can also bind to collagen and albumin in the dermis (the albumin concentration in the aqueous dermal phase being about 0.7 that in serum [40] ). Binding to immobile collagen can impair dermal diffusion; convective transport of albumin into the lymphatics facilitates deeper transport ( Figure   4B ). Blood capillary transport of such drugs is also important. The dermal transport of diclofenac and other highly plasma/dermal protein bound drugs does not appear limited by capillary permeability [6, 20] , consistent with their rapid and reversible distribution between blood capillaries and the extravascular space after intravenous administration [41, 42] . We and others have previously advocated that lipophilicity and solute binding to tissue protein are important in the blood-capillary entry, retention and clearance of drugs in the dermal/deep cutaneous tissues [9, 20, [43] [44] [45] . The fraction unbound of diclofenac in tissues fu T is about 0.22, based on a fu of ~0.05 (Table 1) Inter-subject variability in blood vessel availability and a decrease in blood vessel density with depth ( Figure 3 ) may explain the significant differences in maximum diclofenac blood vessel when the ratio is ~1 ("Sampling site I", Figure 5A ), and sampling away from a blood vessel when the ratio is < 0.4 ("Sampling sites II and III"). The deep-to-superficial-tissue concentration ratio appears to decrease exponentially with distance from the vessels.
Figure 5B Here we have used a physiologically-based pharmacokinetic dispersion-diffusionelimination model. In earlier papers on deep tissue penetration after topical application, we used a compartment-in-series model, defining transport between tissues by a range of intercompartmental and elimination clearances [45, 55, 56] . A limitation in the current work is the implicit assumption of constant elimination with depth. In reality (see Figure 3 ) blood and lymphatic surface area decreases with depth. Our studies of various rat tissue blood flows using microspheres suggest that the blood flow in the subcutaneous tissue and fat pad is lower than in dermis, but blood flow in muscle tissue is higher [48] . Higher levels in the lower dermis may result from lower blood-flow elimination, but higher levels in muscle tissue may arise from greater blood transport than predicted by our model. A disadvantage of the compartment-inseries model is the inability to find determinants to the various clearances obtained by regression.
Consistent with the present model, vasoconstriction led to a greater reduction in the fascia and superficial muscle concentrations for the highly plasma protein bound salicylic acid than for the poorly bound lidocaine [49], whereas vasodilation promoted the skin penetration of methyl salicylate [15] . Deep tissue levels and the elimination of drugs with varying physiochemical properties depend on the relative binding to deep tissue and to plasma proteins [10, 20] .
In conclusion, our analysis of available human cutaneous microdialysis data (Table 1 , [16, 17] ) and reanalysis of available animal data shows that while drugs are transported in deeper tissues by diffusion, transport of plasma protein bound and sufficiently lipophilic drugs can also occur through the blood and lymphatic systems as well as via interstitial convection, and that The skin layer characterization (dermis, subcutis, muscle) corresponding to the cited microdialysis probe depths is obtained from information in [72, 73] . Figure 5B 
